Objective
This project targets at combating diseases such as influenza and SARS. We propose to develop the influenza delNSl virus as a vector for antigens of foreign pathogens such as the SARS-associated coronavirus (SARS-CoV) and influenza virus. Candidate vaccines expressing SARS-CoV antigens as well as candidate vaccines expressing influenza virus antigens will be developed and tested in phase I clinical trials.
An important feature of the delNSl vector is, that deleting the pathogenicity factor NS1 not only leads to an attenuated phenotype but also results in stimulating an efficient immune response in the host. These are highly advantageous properties for a vaccine vector. In the case of the chimeric influenza delNS 1 vaccine, expressing antigens from different influenza types by the delNSl vector would eliminate the current need to combine three different influenza virus strains for vaccination. Therefore, production and purification costs will be significantly reduced, resulting in a cheaper vaccine.
The complementary constellation, the quality of the partners, efficient project management and availability of the combined resources will enable to successfully reach the goals of this project. It will allow the SMEs to significantly shorten the time necessary for the preclinical development phase and will bring the proposed chimeric vaccine viruses a major step closer to a marketable stage. Therefore, the project will contribute to the integration of partners in European research networks and, by its highly innovative features strengthen the European research.
Through the involvement of partners from the Czech republic and from Slovenia this project contributes to the integration of future member countries. Due to the enormous market potential, significant earnings can be expected. The patents, virus strains and technologies generated through these project will allow the SMEs to negotiate significant upfront, licensing and royalties payments from pharmaceuticals companies.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenza
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Call for proposal
FP6-2002-SME-1
See other projects for this call
Funding Scheme
Cooperative - SMEs-Co-operative research contractsCoordinator
VIENNA
Austria